SGYP


Synergy Pharmaceuticals (SGYP) Stock Crash Holds an Important Lesson, Says Biotech Spectator

As Bausch Health (BHC) attempts to swallow up bankrupt Synergy Pharmaceuticals (SGYP), Seeking Alpha blogger Biotech Spectator (BS) says Synergy’s beloved Irritable Bowel …

Bausch Health (BHC) (Tries) to Save Synergy Pharmaceuticals (SGYP) While It’s Down; Analyst Sees Upside for the Stock

Bausch Health Companies (BHC) announced today it will acquire some assets of Synergy Pharmaceuticals, which is being called the “stalking horse” agreement – …

Synergy Pharmaceuticals (SGYP) Stock: When Enough Is Enough

As Synergy Pharmaceuticals (SGYP) trudges its way through economic difficulty, the company has more unfortunate news up ahead — BTIG’s analyst Tim Chiang …

Synergy Pharmaceuticals (SGYP) May Be Filing for Bankruptcy — and Its Stock Price Is Now Around 40 Cents

Synergy Pharmaceuticals (SGYP) is considering filing for bankruptcy protection as it faces a large debt repayment. Shares of Synergy plunged as much as …

Ladenburg Pounds the Table on Synergy Pharmaceuticals (SGYP)

Ladenburg analyst Kevin Degeeter was out pounding the table on shares of Synergy Pharmaceuticals (NASDAQ:SGYP), initiating a Buy rating and price target of $3.00, which …

Analyst Shares Two Cents on Synergy Pharmaceuticals (SGYP) Following DDW Conference

As Synergy Pharmaceuticals (NASDAQ:SGYP) revealed new clinical data during the Digestive Disease Week (DDW) conference, H.C.

Synergy Pharmaceuticals (SGYP): Can Trulance Uptake Grow Stronger? Oppenheimer and Cantor Weigh in

Oppenheimer’s Christopher Liu and Cantor’s William Tanner see potential in Synergy’s Trulance, even if its momentum is not full steam ahead just yet.

Synergy Pharmaceuticals (SGYP) GI Asset Trulance Volumes Just Keep Getting Better; BTIG Weighs In

BTIG’s Tim Chiang is out with a positive research note, singing the praises of SGYP and 1Q earnings that put Trulance’s potential in the limelight.

Synergy Pharmaceuticals (SGYP) Trulance Launch Looks Positive from the Eyes of Canaccord

Canaccord’s John Newman is out with bullish praise for Synergy, even if investors are less-than-enthused on back of Q1 results.

Synergy Pharmaceuticals (SGYP) Stock Sinks on Disappointing Earnings Update

Synergy Pharmaceuticals (NASDAQ:SGYP) saw its shares crater 10% in after-hours trading Thursday, after the drug maker revealed disappointing first-quarter earnings results. To put …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts